Anhui Huaheng Biotechnology Co. Ltd. A Market Cap ($618.54 Million)
Market Cap & Net Worth: Anhui Huaheng Biotechnology Co. Ltd. A (688639)
Anhui Huaheng Biotechnology Co. Ltd. A market cap. Anhui Huaheng Biotechnology Co. Ltd. A (SHG:688639) has a market capitalization of $618.54 Million (CN¥4.23 Billion) as of November 8, 2026. Listed on the SHG stock exchange, this China-based company holds position #10833 globally and #2937 in its home market, demonstrating a 10.97% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Anhui Huaheng Biotechnology Co. Ltd. A's stock price CN¥16.90 by its total outstanding shares 250115693 (250.12 Million). Also see Anhui Huaheng Biotechnology Co. Ltd. A cash flow conversion for how efficiently the company converts equity into cash flow.
Anhui Huaheng Biotechnology Co. Ltd. A Market Cap History (2021–2026)
Anhui Huaheng Biotechnology Co. Ltd. A market cap history from 2021 to 2026. Data shows growth from $2.18 Billion to $618.54 Million (0.86% CAGR). Check Anhui Huaheng Biotechnology Co. Ltd. A share price for real-time trading data and today's change.
Anhui Huaheng Biotechnology Co. Ltd. A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Anhui Huaheng Biotechnology Co. Ltd. A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Anhui Huaheng Biotechnology Co. Ltd. A (688639) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.42x
Anhui Huaheng Biotechnology Co. Ltd. A's market cap is 0.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.01x
Anhui Huaheng Biotechnology Co. Ltd. A's market cap is 9.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.18 Billion | $954.10 Million | $168.24 Million | 2.28x | 12.94x |
| 2022 | $2.63 Billion | $1.42 Billion | $320.03 Million | 1.85x | 8.21x |
| 2023 | $3.11 Billion | $1.94 Billion | $449.06 Million | 1.61x | 6.93x |
| 2024 | $1.18 Billion | $2.18 Billion | $189.52 Million | 0.54x | 6.22x |
| 2025 | $1.19 Billion | $2.86 Billion | $132.41 Million | 0.42x | 9.01x |
Competitor Companies of 688639 by Market Capitalization
Companies near Anhui Huaheng Biotechnology Co. Ltd. A in the global market cap rankings as of November 8, 2026. Also see Anhui Huaheng Biotechnology Co. Ltd. A balance sheet assets for a full breakdown of the balance sheet.
Key companies related to Anhui Huaheng Biotechnology Co. Ltd. A by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Anhui Huaheng Biotechnology Co. Ltd. A (2021–2026)
Market capitalization of Anhui Huaheng Biotechnology Co. Ltd. A from 2021 to today. Between 2021 and today, Anhui Huaheng Biotechnology Co. Ltd. A's market cap moved from $2.18 Billion to $ 618.54 Million, with a yearly change of 0.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥618.54 Million | -48.13% |
| 2025 | CN¥1.19 Billion | +1.15% |
| 2024 | CN¥1.18 Billion | -62.14% |
| 2023 | CN¥3.11 Billion | +18.52% |
| 2022 | CN¥2.63 Billion | +20.65% |
| 2021 | CN¥2.18 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 8th, 2026 the market cap of Anhui Huaheng Biotechnology Co. Ltd. A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $618.54 Million USD |
| MoneyControl | $618.54 Million USD |
| MarketWatch | $618.54 Million USD |
| marketcap.company | $618.54 Million USD |
| Reuters | $618.54 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material mon… Read more